Investment

Cell & Gene Therapy

Cell therapy's second act: why Boston is still winning

Four years after the first wave of CAR-T IPOs, Massachusetts is quietly becoming the centre of gravity for the next generation of cell therapies — this time, for solid tumours.

When the FDA approved the first CAR-T therapy for leukaemia in 2017, the assumption across the industry was that the blood cancer playbook would translate quickly into solid tumours. It did not.

Mark Walker  · 
AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Biotech

Taranis Builds Saudi Biotech Ecosystem

Taranis Capital launches a biotech fund and Helix8 incubator to accelerate Saudi Arabia’s life sciences ambitions under Vision 2030.

Foundations Before Breakthroughs: Building Saudi Arabia’s Biotech Future from First Principles

How Taranis Capital’s Biotech Growth Fund and the Helix8 incubator are answering the Kingdom’s earliest-stage challenge

The Biotech Times Editorial Team  · 
Biotech

PetMed Express confirms revised $3 takeover bid from SilverCape

SilverCape Investments has lowered its unsolicited offer to $3.00 per share, down from $4.00 in December, as PetMeds' board evaluates its options.
SilverCape Investments has lowered its unsolicited offer to $3.00 per share, down from $4.00 in December, as PetMeds' board evaluates its options.
The Biotech Times Editorial Team  · 
Genomics

Oryzon Genomics raises €12m and secures €25m COFIDES commitment

The Barcelona epigenetics biotech priced 4.4 million new shares at €2.70 each and secured a €25m anchor commitment from Spain's Social Impact
The Barcelona epigenetics biotech priced 4.4 million new shares at €2.70 each and secured a €25m anchor commitment from Spain's Social Impact
The Biotech Times Editorial Team  · 
Bioinformatics
Biologics

Corten Capital and Ampersand acquire Beacon Intelligence in PE buyout

The deal separates Beacon from the Hanson Wade Group, giving the R&D intelligence platform independent status backed by Corten's €680m second fund.
The deal separates Beacon from the Hanson Wade Group, giving the R&D intelligence platform independent status backed by Corten's €680m second fund.
The Biotech Times Editorial Team  · 
Biologics

Junshi Biosciences licenses IL-17A antibody roconkibart to Fosun Wanbang

Junshi Biosciences will receive RMB215m upfront plus milestones and royalties under a Greater China licensing deal for its anti-IL-17A antibody.
Junshi Biosciences will receive RMB215m upfront plus milestones and royalties under a Greater China licensing deal for its anti-IL-17A antibody.
The Biotech Times Editorial Team  · 
Biologics

GNI Group completes JPY 44.8bn acquisition of Ayumi Pharmaceutical

GNI Group has acquired Ayumi Pharmaceutical from Blackstone, adding an 83% Japanese acetaminophen market share to its four-region biopharma platform.
GNI Group has acquired Ayumi Pharmaceutical from Blackstone, adding an 83% Japanese acetaminophen market share to its four-region biopharma platform.
The Biotech Times Editorial Team  · 
Biologics

Nicox partner Kowa files NDA for NCX 470 glaucoma eye drop

Kowa's US NDA submission for the nitric oxide-donating bimatoprost drop triggers a €3m milestone and targets FDA approval by mid-2027.
Kowa's US NDA submission for the nitric oxide-donating bimatoprost drop triggers a €3m milestone and targets FDA approval by mid-2027.
The Biotech Times Editorial Team  · 
Biologics

Abivax prices upsized $800M ADS offering to fund obefazimod launch

The Paris-listed biotech upsized its US public offering from $600M to $800M, extending its cash runway to Q2 2029 ahead of a potential obefazimod
The Paris-listed biotech upsized its US public offering from $600M to $800M, extending its cash runway to Q2 2029 ahead of a potential obefazimod
The Biotech Times Editorial Team  · 
Digital Health

Startup Coalition and DSIT launch Pitch in Whitehall competition

UK startups have until 24 July to apply for a government proof-of-concept contract under the Green Compute challenge.
UK startups have until 24 July to apply for a government proof-of-concept contract under the Green Compute challenge.
The Biotech Times Editorial Team  · 
Regulatory Science

Serenity Medical wins FDA Breakthrough Device tag for tinnitus stent

The Shepherd Stent System targets venous sinus stenosis in severe pulsatile tinnitus, a condition linked to depression and elevated suicide risk.
The Shepherd Stent System targets venous sinus stenosis in severe pulsatile tinnitus, a condition linked to depression and elevated suicide risk.
The Biotech Times Editorial Team  · 
Biologics

Moleculin's Annamycin hits 3x control CR rate in R/R AML interim

Interim MIRACLE trial data showed Annamycin complete remission rates up to 43% versus 12% for control in relapsed or refractory AML patients.
Interim MIRACLE trial data showed Annamycin complete remission rates up to 43% versus 12% for control in relapsed or refractory AML patients.
The Biotech Times Editorial Team  · 
Biologics

Lycia Therapeutics raises $75m Series D for LYTAC pipeline

The oversubscribed round, co-led by Janus Henderson and Balyasny, funds two autoimmune degrader candidates toward Phase 1 proof-of-concept.
The oversubscribed round, co-led by Janus Henderson and Balyasny, funds two autoimmune degrader candidates toward Phase 1 proof-of-concept.
The Biotech Times Editorial Team  · 

LENZ Therapeutics signs fifth ex-US VIZZ deal with Arrotex

LENZ Therapeutics has licensed VIZZ to Australia's largest pharma distributor, marking its fifth international partnership for the FDA-approved presbyopia eye drop.
LENZ Therapeutics has licensed VIZZ to Australia's largest pharma distributor, marking its fifth international partnership for the FDA-approved presbyopia eye drop.
The Biotech Times Editorial Team  · 
Bioprocessing

TISSIUM raises €60m to back COAPTIUM launch and pipeline growth

The Paris-based MedTech has combined a €30m Series D2 with a €30m EIB facility to fund US commercialisation of its FDA-cleared polymer repair
The Paris-based MedTech has combined a €30m Series D2 with a €30m EIB facility to fund US commercialisation of its FDA-cleared polymer repair
The Biotech Times Editorial Team  · 
Biologics

Lilly's $7.8bn Centessa acquisition cleared by English High Court

Eli Lilly's scheme of arrangement to acquire OX2R-focused Centessa Pharmaceuticals has been sanctioned by the High Court, with closing expected on 24 June.
Eli Lilly's scheme of arrangement to acquire OX2R-focused Centessa Pharmaceuticals has been sanctioned by the High Court, with closing expected on 24 June.
The Biotech Times Editorial Team  · 
Digital Health

CosmoFarm posts record $15m Q2 revenue on pharmacy network growth

The Athens-based pharmaceutical wholesaler added over 80 pharmacies in Q2 2026, lifting Cosmos Health's annualised revenue run-rate beyond $60 million.
The Athens-based pharmaceutical wholesaler added over 80 pharmacies in Q2 2026, lifting Cosmos Health's annualised revenue run-rate beyond $60 million.
The Biotech Times Editorial Team  · 
Diagnostics
Biotech

Trinity Biotech wins 2m TrinScreen HIV order; Q1 revenue up 43%

Trinity Biotech secured orders for over 2 million TrinScreen HIV rapid tests, supporting 2026 targets as Q1 revenue rose 43% to $10.8m.
Trinity Biotech secured orders for over 2 million TrinScreen HIV rapid tests, supporting 2026 targets as Q1 revenue rose 43% to $10.8m.
The Biotech Times Editorial Team  · 
Subscribe to Investment